Aethlon Medical Posts Q1 FY2027 Net Loss of $1.55M; Cash Runway Extended to 12 Months

summarizeSummary

Aethlon Medical reported a narrower Q1 FY2027 net loss of $1.55 million and extended its cash runway to at least twelve months, supported by ATM sales and a $4.0 million July offering.

check_boxKey Events · Earnings and Guidance · AEMD

• Q1 FY2027 Net Loss Narrows

  Net loss of $1,547,912 for the three months ended June 30, 2026, down from $1,761,858 in the prior-year period, driven by lower professional fees and G&A expenses.

• ATM Sales Add $1.82M Net Proceeds

  The company sold 160,028 shares under its at-the-market program, generating gross proceeds of $1,904,000 and net proceeds of $1,821,000 for working capital.

• Cash Runway Extended to 12 Months

  Management states that cash of $4.93 million as of June 30, 2026, plus proceeds from the July 2026 offering, will fund operations for at least twelve months, alleviating the prior going-concern doubt.

• July 2026 Offering Completed

  Subsequent to quarter end, the company completed a registered best-efforts offering of common stock and warrants, generating gross proceeds of approximately $4.0 million.

auto_awesomeAnalysis · AEMD · Industrial Applications And Services

First-quarter fiscal 2027 results show a net loss of $1.55 million, a 12% improvement from the prior-year period, while the company raised $1.82 million in net proceeds through its ATM program. Management states that cash on hand plus the $4.0 million July 2026 offering proceeds are sufficient to fund operations for at least twelve months, removing the near-term going-concern overhang that had been flagged in the prior 10-K. The reverse stock split and subsequent offering are also disclosed, providing clarity on the company's capital structure.